Aurobindo Pharma announced that on 21 February 2020, the company received a communication that the inspection conducted by the
U.S. Food and Drug Administration (USFDA) at the company's Unit IV, from 04 November 2019 to 13 November 2019, is still open and under review, by way of rescindment of 90-day VAI letter that was issued by
them on 18 February 2020.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
